Related Experiment Video

Updated: Jul 19, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Aspirin reduces anticardiolipin antibodies in patients with coronary artery disease

I Ikonomidis1, J Lekakis, G Vamvakou

  • 1Second Cardiology Department, Attikon University Hospital, University of Athens, N Chalkidona, Athens, Greece. ignoik@otenet.gr

European Journal of Clinical Investigation
|November 8, 2006
PubMed

Insights

Aspirin treatment significantly reduced anticardiolipin antibody (aCL) levels in patients with chronic coronary artery disease (CAD). This reduction in immunoglobulin (Ig)A and IgG aCL correlated with decreased C-reactive protein (CRP) levels.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Elevated anticardiolipin antibodies (aCL) are linked to adverse outcomes in coronary artery disease (CAD) due to prothrombotic activity.
  • Chronic CAD patients exhibit higher immunoglobulin (Ig)A and IgG aCL levels compared to healthy individuals.

Purpose of the Study:

  • To investigate the impact of aspirin on aCL levels in patients with chronic CAD.
  • To explore the relationship between aspirin, aCL, and C-reactive protein (CRP) in CAD patients.

Main Methods:

  • A double-blind, cross-over trial involving 40 chronic CAD patients and 40 controls.
  • Patients received 300 mg daily aspirin or placebo for 12-day periods before coronary artery bypass graft surgery.
  • Serum levels of IgA, IgG, IgM-aCL, and CRP were measured.

Main Results:

  • Patients with CAD had higher IgA and IgG aCL levels than controls.
  • Aspirin treatment significantly reduced IgA, IgG aCL, and CRP levels compared to placebo.
  • The reduction in IgA and IgG aCL after aspirin was correlated with CRP reduction.

Conclusions:

  • Daily aspirin (300 mg) effectively lowers serum IgA and IgG aCL levels in chronic CAD patients.
  • This effect occurs in parallel with a reduction in CRP, suggesting a shared pathophysiological mechanism.
  • Findings provide an additional explanation for aspirin's benefits in managing chronic CAD.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...